LeMaitre Vascular (LMAT)
(Delayed Data from NSDQ)
$85.01 USD
-1.24 (-1.44%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $84.81 -0.20 (-0.24%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth C Momentum C VGM
LeMaitre Vascular (LMAT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$79.17 | $100.00 | $70.00 | -8.21% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for LeMaitre Vascular comes to $79.17. The forecasts range from a low of $70.00 to a high of $100.00. The average price target represents a decline of 8.21% from the last closing price of $86.25.
Analyst Price Targets (6 )
Broker Rating
LeMaitre Vascular currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, six are Strong Buy, representing 75% of all recommendations. A month ago, Strong Buy represented 75%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/LMAT.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.50 | 1.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/31/2024 | Roth Capital Partners | Jason Wittes | Not Available | Strong Buy |
5/3/2024 | Lake Street Capital Markets | Brooks G O'Neil | Strong Buy | Strong Buy |
5/3/2024 | JMP Securities | David L Turkaly | Strong Buy | Strong Buy |
5/3/2024 | Barrington Research | Michael J Petusky | Strong Buy | Strong Buy |
5/2/2024 | Not Identified | Not Identified | Hold | Hold |
4/26/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/28/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/6/2024 | KeyBanc Capital Markets | Brett Fishbin | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 8 |
Average Target Price | $79.17 |
LT Growth Rate | 18.50% |
Industry | Medical - Products |
Industry Rank by ABR | 101 of 253 |
Current Quarter EPS Est: | 0.43 |